What every dentist should know about the "z-sedatives".
Identifieur interne : 000408 ( Main/Exploration ); précédent : 000407; suivant : 000409What every dentist should know about the "z-sedatives".
Auteurs : Wm Stuart Mckenzie [États-Unis] ; Morton RosenbergSource :
- Journal of the Massachusetts Dental Society [ 0025-4800 ] ; 2007.
Descripteurs français
- KwdFr :
- Acétamides (métabolisme), Composés azabicycliques (effets indésirables), Composés azabicycliques (métabolisme), Eszopiclone (MeSH), Humains (MeSH), Hypnotiques et sédatifs (effets indésirables), Hypnotiques et sédatifs (métabolisme), Interactions médicamenteuses (MeSH), Pipérazines (effets indésirables), Pipérazines (métabolisme), Pyridines (effets indésirables), Pyridines (métabolisme), Pyrimidines (métabolisme), Troubles de l'endormissement et du maintien du sommeil (traitement médicamenteux), Zolpidem (MeSH).
- MESH :
- effets indésirables : Composés azabicycliques, Hypnotiques et sédatifs, Pipérazines, Pyridines.
- métabolisme : Acétamides, Composés azabicycliques, Hypnotiques et sédatifs, Pipérazines, Pyridines, Pyrimidines.
- traitement médicamenteux : Troubles de l'endormissement et du maintien du sommeil.
- Eszopiclone, Humains, Interactions médicamenteuses, Zolpidem.
English descriptors
- KwdEn :
- Acetamides (metabolism), Azabicyclo Compounds (adverse effects), Azabicyclo Compounds (metabolism), Drug Interactions (MeSH), Eszopiclone (MeSH), Humans (MeSH), Hypnotics and Sedatives (adverse effects), Hypnotics and Sedatives (metabolism), Piperazines (adverse effects), Piperazines (metabolism), Pyridines (adverse effects), Pyridines (metabolism), Pyrimidines (metabolism), Sleep Initiation and Maintenance Disorders (drug therapy), Zolpidem (MeSH).
- MESH :
- chemical , adverse effects : Azabicyclo Compounds, Hypnotics and Sedatives, Piperazines, Pyridines.
- chemical , metabolism : Acetamides, Azabicyclo Compounds, Hypnotics and Sedatives, Piperazines, Pyridines, Pyrimidines.
- drug therapy : Sleep Initiation and Maintenance Disorders.
- Drug Interactions, Eszopiclone, Humans, Zolpidem.
Abstract
According to the National Institutes of Health, approximately 30 percent of all Americans complain of sleep disruption, while 10 percent display symptoms congruent with chronic insomnia. One of the most common treatments for insomnia is prescription sleep medications that help people fall asleep and remain asleep. Historically barbiturates were initially popular for treating insomnia, but their long "hangover" effect made them easily replaced with the introduction of the benzodiazepines. Triazolam (Halcion), diazepam (Valium), and oxazepam (Serax) rapidly became the treatment of choice for insomnia. Recently a new class of nonbenzodiazepines---the "z-sedatives"--has overtaken the older benzodiazepines as the most commonly prescribed sleep medications. The three most popular z-drugs are zolpidem (Ambien), zaleplon (Sonata), and eszopiclone (Lunesta). The Food and Drug Administration (FDA) also recently approved the production of zolpidem tartrate, a generic form of Ambien. Many dentists prescribe these medications for patients who have difficulty sleeping the night prior to an appointment or as a procedural sedative. With 43 million prescriptions for sleep medications filled in 2005, generating $2.7 billion for pharmaceutical companies, it is important that dentists be aware of these drugs' mechanism of action and potential drug interactions.
PubMed: 18069595
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">What every dentist should know about the "z-sedatives".</title><author><name sortKey="Mckenzie, Wm Stuart" sort="Mckenzie, Wm Stuart" uniqKey="Mckenzie W" first="Wm Stuart" last="Mckenzie">Wm Stuart Mckenzie</name><affiliation wicri:level="1"><nlm:affiliation>Tufts University School of Dental Medicine, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Tufts University School of Dental Medicine</wicri:regionArea></affiliation></author><author><name sortKey="Rosenberg, Morton" sort="Rosenberg, Morton" uniqKey="Rosenberg M" first="Morton" last="Rosenberg">Morton Rosenberg</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:18069595</idno><idno type="pmid">18069595</idno><idno type="wicri:Area/Main/Corpus">000403</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000403</idno><idno type="wicri:Area/Main/Curation">000403</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000403</idno><idno type="wicri:Area/Main/Exploration">000403</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">What every dentist should know about the "z-sedatives".</title><author><name sortKey="Mckenzie, Wm Stuart" sort="Mckenzie, Wm Stuart" uniqKey="Mckenzie W" first="Wm Stuart" last="Mckenzie">Wm Stuart Mckenzie</name><affiliation wicri:level="1"><nlm:affiliation>Tufts University School of Dental Medicine, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Tufts University School of Dental Medicine</wicri:regionArea></affiliation></author><author><name sortKey="Rosenberg, Morton" sort="Rosenberg, Morton" uniqKey="Rosenberg M" first="Morton" last="Rosenberg">Morton Rosenberg</name></author></analytic><series><title level="j">Journal of the Massachusetts Dental Society</title><idno type="ISSN">0025-4800</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (metabolism)</term><term>Azabicyclo Compounds (adverse effects)</term><term>Azabicyclo Compounds (metabolism)</term><term>Drug Interactions (MeSH)</term><term>Eszopiclone (MeSH)</term><term>Humans (MeSH)</term><term>Hypnotics and Sedatives (adverse effects)</term><term>Hypnotics and Sedatives (metabolism)</term><term>Piperazines (adverse effects)</term><term>Piperazines (metabolism)</term><term>Pyridines (adverse effects)</term><term>Pyridines (metabolism)</term><term>Pyrimidines (metabolism)</term><term>Sleep Initiation and Maintenance Disorders (drug therapy)</term><term>Zolpidem (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acétamides (métabolisme)</term><term>Composés azabicycliques (effets indésirables)</term><term>Composés azabicycliques (métabolisme)</term><term>Eszopiclone (MeSH)</term><term>Humains (MeSH)</term><term>Hypnotiques et sédatifs (effets indésirables)</term><term>Hypnotiques et sédatifs (métabolisme)</term><term>Interactions médicamenteuses (MeSH)</term><term>Pipérazines (effets indésirables)</term><term>Pipérazines (métabolisme)</term><term>Pyridines (effets indésirables)</term><term>Pyridines (métabolisme)</term><term>Pyrimidines (métabolisme)</term><term>Troubles de l'endormissement et du maintien du sommeil (traitement médicamenteux)</term><term>Zolpidem (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Azabicyclo Compounds</term><term>Hypnotics and Sedatives</term><term>Piperazines</term><term>Pyridines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Acetamides</term><term>Azabicyclo Compounds</term><term>Hypnotics and Sedatives</term><term>Piperazines</term><term>Pyridines</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Sleep Initiation and Maintenance Disorders</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Composés azabicycliques</term><term>Hypnotiques et sédatifs</term><term>Pipérazines</term><term>Pyridines</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Acétamides</term><term>Composés azabicycliques</term><term>Hypnotiques et sédatifs</term><term>Pipérazines</term><term>Pyridines</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Troubles de l'endormissement et du maintien du sommeil</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Interactions</term><term>Eszopiclone</term><term>Humans</term><term>Zolpidem</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Eszopiclone</term><term>Humains</term><term>Interactions médicamenteuses</term><term>Zolpidem</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">According to the National Institutes of Health, approximately 30 percent of all Americans complain of sleep disruption, while 10 percent display symptoms congruent with chronic insomnia. One of the most common treatments for insomnia is prescription sleep medications that help people fall asleep and remain asleep. Historically barbiturates were initially popular for treating insomnia, but their long "hangover" effect made them easily replaced with the introduction of the benzodiazepines. Triazolam (Halcion), diazepam (Valium), and oxazepam (Serax) rapidly became the treatment of choice for insomnia. Recently a new class of nonbenzodiazepines---the "z-sedatives"--has overtaken the older benzodiazepines as the most commonly prescribed sleep medications. The three most popular z-drugs are zolpidem (Ambien), zaleplon (Sonata), and eszopiclone (Lunesta). The Food and Drug Administration (FDA) also recently approved the production of zolpidem tartrate, a generic form of Ambien. Many dentists prescribe these medications for patients who have difficulty sleeping the night prior to an appointment or as a procedural sedative. With 43 million prescriptions for sleep medications filled in 2005, generating $2.7 billion for pharmaceutical companies, it is important that dentists be aware of these drugs' mechanism of action and potential drug interactions.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18069595</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0025-4800</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Season>Fall</Season></PubDate></JournalIssue><Title>Journal of the Massachusetts Dental Society</Title><ISOAbbreviation>J Mass Dent Soc</ISOAbbreviation></Journal><ArticleTitle>What every dentist should know about the "z-sedatives".</ArticleTitle><Pagination><MedlinePgn>44-5</MedlinePgn></Pagination><Abstract><AbstractText>According to the National Institutes of Health, approximately 30 percent of all Americans complain of sleep disruption, while 10 percent display symptoms congruent with chronic insomnia. One of the most common treatments for insomnia is prescription sleep medications that help people fall asleep and remain asleep. Historically barbiturates were initially popular for treating insomnia, but their long "hangover" effect made them easily replaced with the introduction of the benzodiazepines. Triazolam (Halcion), diazepam (Valium), and oxazepam (Serax) rapidly became the treatment of choice for insomnia. Recently a new class of nonbenzodiazepines---the "z-sedatives"--has overtaken the older benzodiazepines as the most commonly prescribed sleep medications. The three most popular z-drugs are zolpidem (Ambien), zaleplon (Sonata), and eszopiclone (Lunesta). The Food and Drug Administration (FDA) also recently approved the production of zolpidem tartrate, a generic form of Ambien. Many dentists prescribe these medications for patients who have difficulty sleeping the night prior to an appointment or as a procedural sedative. With 43 million prescriptions for sleep medications filled in 2005, generating $2.7 billion for pharmaceutical companies, it is important that dentists be aware of these drugs' mechanism of action and potential drug interactions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McKenzie</LastName><ForeName>Wm Stuart</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Tufts University School of Dental Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Morton</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Mass Dent Soc</MedlineTA><NlmUniqueID>7503082</NlmUniqueID><ISSNLinking>0025-4800</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081">Acetamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053961">Azabicyclo Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006993">Hypnotics and Sedatives</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>7K383OQI23</RegistryNumber><NameOfSubstance UI="D000077334">Zolpidem</NameOfSubstance></Chemical><Chemical><RegistryNumber>S62U433RMH</RegistryNumber><NameOfSubstance UI="C085665">zaleplon</NameOfSubstance></Chemical><Chemical><RegistryNumber>UZX80K71OE</RegistryNumber><NameOfSubstance UI="D000069582">Eszopiclone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>D</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053961" MajorTopicYN="N">Azabicyclo Compounds</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069582" MajorTopicYN="N">Eszopiclone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006993" MajorTopicYN="N">Hypnotics and Sedatives</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007319" MajorTopicYN="N">Sleep Initiation and Maintenance Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077334" MajorTopicYN="N">Zolpidem</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18069595</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Rosenberg, Morton" sort="Rosenberg, Morton" uniqKey="Rosenberg M" first="Morton" last="Rosenberg">Morton Rosenberg</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Mckenzie, Wm Stuart" sort="Mckenzie, Wm Stuart" uniqKey="Mckenzie W" first="Wm Stuart" last="Mckenzie">Wm Stuart Mckenzie</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SuicidDentistV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000408 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000408 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SuicidDentistV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:18069595
|texte= What every dentist should know about the "z-sedatives".
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:18069595" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SuicidDentistV1
| This area was generated with Dilib version V0.6.39. |  |